High IL-23^(+)cells infiltration correlates with worse clinical outcomes and abiraterone effectiveness in patients with prostate cancer  

作　　者：Zheng Liu Jun-Yu Zhang Yun-Jie Yang Kun Chang Qi-Feng Wang Yun-Yi Kong Bo Dai 

机构地区：[1]Department of Urology,Fudan University Shanghai Cancer Center,Shanghai 200032,China [2]Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China [3]Department of Pathology,Fudan University Shanghai Cancer Center,Shanghai 200032,China

出　　处：《Asian Journal of Andrology》2022年第2期147-153,共7页亚洲男性学杂志（英文版）

基　　金：This study was supported by grant from the National Key R&D Program of China(2017YFC0114303);grant from the Natural Science Foundation of Science and Technology Commission of Shanghai Municipality(20ZR1412300);grant from the Medical Innovation Research Project of the Science and Technology Commission of Shanghai Municipality(No.20Y11905000);grants from the AoXiang Project of the Shanghai Anti-Cancer Association(SACA-AX201908 and SACA-AX202005);All these study sponsors have no roles in the study design,collection,analysis,and interpretation of data.

摘　　要：Individualized treatment of prostate cancer depends on an accurate stratification of patients who are sensitive to various treatments.Interleukin-23(IL-23)was reported to play a significant role in prostate cancer.Here,we aimed to explore the clinical value of IL-23-secreting(IL-23^(+))cells in prostate cancer patients.We evaluated interleukin-23A(IL-23A)expression in The Cancer Genome Atlas database and retrospectively enrolled 179 treatment-naive metastatic prostate cancer patients diagnosed in our institute between June 2012 and December 2014.IL-23^(+)cells were stained and evaluated via immunohistochemistry.Further,survival and multivariate Cox regression analyses were conducted to explore the prognostic value of IL-23^(+)cells.We found that IL-23A expression correlated with disease progression,while IL-23^(+)cells were clearly stained within prostate cancer tissue.Patients with higher Gleason scores and multiple metastatic lesions tended to have more IL-23^(+)cell infiltration.Further analyses showed that patients with higher levels of IL-23^(+)cells had significantly worse overall survival(hazard ratio[HR]=2.996,95%confidence interval[95%CI]:1.812–4.955;P=0.001)and a higher risk of developing castration resistance(HR=2.725,95%CI:1.865–3.981;P=0.001).Moreover,subgroup analyses showed that when patients progressed to a castration-resistant status,the prognostic value of IL-23^(+)cells was observed only in patients treated with abiraterone instead of docetaxel.Therefore,we showed that high IL-23^(+)cell infiltration is an independent prognosticator in patients with metastatic prostate cancer.IL-23^(+)cell infiltration may correlate with abiraterone effectiveness in castration-resistant prostate cancer patients.

关 键 词：abiraterone acetate INTERLEUKIN-23 prognosis prostate cancer 

分 类 号：R737.25[医药卫生—肿瘤]